BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

250 related articles for article (PubMed ID: 30446732)

  • 21. ABC-transporter upregulation mediates resistance to the CDK7 inhibitors THZ1 and ICEC0942.
    Sava GP; Fan H; Fisher RA; Lusvarghi S; Pancholi S; Ambudkar SV; Martin LA; Charles Coombes R; Buluwela L; Ali S
    Oncogene; 2020 Jan; 39(3):651-663. PubMed ID: 31530935
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pharmacological inhibition of CDK7 by THZ1 impairs tumor growth in p53-mutated HNSCC.
    Ge H; Yao Y; Jiang Y; Wu X; Wang Y
    Oral Dis; 2022 Apr; 28(3):611-620. PubMed ID: 33503275
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Transcriptional CDK inhibitors, CYC065 and THZ1 promote Bim-dependent apoptosis in primary and recurrent GBM through cell cycle arrest and Mcl-1 downregulation.
    Juric V; Hudson L; Fay J; Richards CE; Jahns H; Verreault M; Bielle F; Idbaih A; Lamfers MLM; Hopkins AM; Rehm M; Murphy BM
    Cell Death Dis; 2021 Aug; 12(8):763. PubMed ID: 34344865
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Combinational therapeutic targeting of BRD4 and CDK7 synergistically induces anticancer effects in head and neck squamous cell carcinoma.
    Zhang W; Ge H; Jiang Y; Huang R; Wu Y; Wang D; Guo S; Li S; Wang Y; Jiang H; Cheng J
    Cancer Lett; 2020 Jan; 469():510-523. PubMed ID: 31765738
    [TBL] [Abstract][Full Text] [Related]  

  • 25. THZ1 targeting CDK7 suppresses STAT transcriptional activity and sensitizes T-cell lymphomas to BCL2 inhibitors.
    Cayrol F; Praditsuktavorn P; Fernando TM; Kwiatkowski N; Marullo R; Calvo-Vidal MN; Phillip J; Pera B; Yang SN; Takpradit K; Roman L; Gaudiano M; Crescenzo R; Ruan J; Inghirami G; Zhang T; Cremaschi G; Gray NS; Cerchietti L
    Nat Commun; 2017 Jan; 8():14290. PubMed ID: 28134252
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Induction of G2/M Cell Cycle Arrest via p38/p21
    Pai JT; Hsu MW; Leu YL; Chang KT; Weng MS
    Molecules; 2021 Aug; 26(17):. PubMed ID: 34500594
    [TBL] [Abstract][Full Text] [Related]  

  • 27. THZ1 Reveals Roles for Cdk7 in Co-transcriptional Capping and Pausing.
    Nilson KA; Guo J; Turek ME; Brogie JE; Delaney E; Luse DS; Price DH
    Mol Cell; 2015 Aug; 59(4):576-87. PubMed ID: 26257281
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Activation of the p53 Transcriptional Program Sensitizes Cancer Cells to Cdk7 Inhibitors.
    Kalan S; Amat R; Schachter MM; Kwiatkowski N; Abraham BJ; Liang Y; Zhang T; Olson CM; Larochelle S; Young RA; Gray NS; Fisher RP
    Cell Rep; 2017 Oct; 21(2):467-481. PubMed ID: 29020632
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Antitumor activity of AZ64 via G2/M arrest in non-small cell lung cancer.
    Xue Y; Ren H; Xiao W; Chu Z; Lee JJ; Mao L
    Int J Oncol; 2012 Nov; 41(5):1798-808. PubMed ID: 22948297
    [TBL] [Abstract][Full Text] [Related]  

  • 30. In vitro and in vivo anti-tumour effects of MPT0B014, a novel derivative aroylquinoline, and in combination with erlotinib in human non-small-cell lung cancer cells.
    Tsai AC; Pai HC; Wang CY; Liou JP; Teng CM; Wang JC; Pan SL
    Br J Pharmacol; 2014 Jan; 171(1):122-33. PubMed ID: 24116948
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Targeting super-enhancer-associated oncogenes in oesophageal squamous cell carcinoma.
    Jiang YY; Lin DC; Mayakonda A; Hazawa M; Ding LW; Chien WW; Xu L; Chen Y; Xiao JF; Senapedis W; Baloglu E; Kanojia D; Shang L; Xu X; Yang H; Tyner JW; Wang MR; Koeffler HP
    Gut; 2017 Aug; 66(8):1358-1368. PubMed ID: 27196599
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Therapeutic Rationale to Target Highly Expressed CDK7 Conferring Poor Outcomes in Triple-Negative Breast Cancer.
    Li B; Ni Chonghaile T; Fan Y; Madden SF; Klinger R; O'Connor AE; Walsh L; O'Hurley G; Mallya Udupi G; Joseph J; Tarrant F; Conroy E; Gaber A; Chin SF; Bardwell HA; Provenzano E; Crown J; Dubois T; Linn S; Jirstrom K; Caldas C; O'Connor DP; Gallagher WM
    Cancer Res; 2017 Jul; 77(14):3834-3845. PubMed ID: 28455421
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A high-throughput screen identifies that CDK7 activates glucose consumption in lung cancer cells.
    Ghezzi C; Wong A; Chen BY; Ribalet B; Damoiseaux R; Clark PM
    Nat Commun; 2019 Nov; 10(1):5444. PubMed ID: 31784510
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Targeting transcription regulation in cancer with a covalent CDK7 inhibitor.
    Kwiatkowski N; Zhang T; Rahl PB; Abraham BJ; Reddy J; Ficarro SB; Dastur A; Amzallag A; Ramaswamy S; Tesar B; Jenkins CE; Hannett NM; McMillin D; Sanda T; Sim T; Kim ND; Look T; Mitsiades CS; Weng AP; Brown JR; Benes CH; Marto JA; Young RA; Gray NS
    Nature; 2014 Jul; 511(7511):616-20. PubMed ID: 25043025
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Targeting CDK7 suppresses super enhancer-linked inflammatory genes and alleviates CAR T cell-induced cytokine release syndrome.
    Wei Y; Li C; Bian H; Qian W; Jin K; Xu T; Guo X; Lu X; Su F
    Mol Cancer; 2021 Jan; 20(1):5. PubMed ID: 33397398
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Heterogeneity of glutamine metabolism in acquired-EGFR-TKI-resistant lung cancer.
    Kim S; Jeon JS; Choi YJ; Baek GH; Kim SK; Kang KW
    Life Sci; 2022 Feb; 291():120274. PubMed ID: 34990648
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Selective CDK7 inhibition with BS-181 suppresses cell proliferation and induces cell cycle arrest and apoptosis in gastric cancer.
    Wang BY; Liu QY; Cao J; Chen JW; Liu ZS
    Drug Des Devel Ther; 2016; 10():1181-9. PubMed ID: 27042010
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Glutaminase-1 stimulates the proliferation, migration, and survival of human endothelial cells.
    Peyton KJ; Liu XM; Yu Y; Yates B; Behnammanesh G; Durante W
    Biochem Pharmacol; 2018 Oct; 156():204-214. PubMed ID: 30144404
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Inhibition of mitotic Aurora kinase A by alisertib induces apoptosis and autophagy of human gastric cancer AGS and NCI-N78 cells.
    Yuan CX; Zhou ZW; Yang YX; He ZX; Zhang X; Wang D; Yang T; Wang NJ; Zhao RJ; Zhou SF
    Drug Des Devel Ther; 2015; 9():487-508. PubMed ID: 25609923
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Blockade of CDK7 Reverses Endocrine Therapy Resistance in Breast Cancer.
    Attia YM; Shouman SA; Salama SA; Ivan C; Elsayed AM; Amero P; Rodriguez-Aguayo C; Lopez-Berestein G
    Int J Mol Sci; 2020 Apr; 21(8):. PubMed ID: 32340192
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.